ProCE Banner Activity

Phase I/II Trial of Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed/Refractory AML

Slideset Download
Conference Coverage

This triplet combination demonstrated encouraging activity in frontline AML, with high CR/CRi rates in patients with TP53wt and TP53mut AML.

Released: December 19, 2022

Expiration: December 18, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen